Efficacy and tolerability of conversion from cyclosporin to azathioprine after kidney transplantation: A review of the evidence

BioDrugs

Volumn 9, Issue 3, 1998, Pages 197-210

  Hollander, Adrianus A M J ^a,c   Van Der Woude, Fokko J ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c JEROEN BOSCH HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BREQUINAR; CALCINEURIN; COTRIMOXAZOLE; CYCLOSPORIN; DILTIAZEM; ERYTHROMYCIN; INTERLEUKIN 2; KETOCONAZOLE; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAFCILLIN; OCTREOTIDE; PREDNISONE; THYMOCYTE ANTIBODY; VERAPAMIL;

BONE MARROW TOXICITY; COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LEUKOPENIA; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA;

EID: 0031923846     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199809030-00003     Document Type: Review

References (130)

1. Schwanz RS, Dameshek W. Drug-induced immunological tolerance. Nature 1959 Jun; 183: 1682-3
2. Calne RY, Alexandre GP, Murray JE. A study of the effects of drugs in prolonged survival of homologous renal transplants in dogs. Ann NY Acad Sci 1962: 99: 743-61
3. Murray JE. Merrill JP. Harrison JH. et al. Prolonged survival of human-kidney homografts by immunosuppressive drug therapy. N Engl J Med 1963: 268: 1315-23
4. European Multicentre Trial Group. Cyclosporin in cadaveric renal transplantation: one year follow-up of a rnulticentre trial. Lancet 1983 Oct; 11:986-9
5. Canadian Multicentre Transplant Study Group. A randomized clinical trial of cyclosporin in cadaveric renal transplantation. N Engl J Med 1983: 309: 809-15
6. Hall BM. Tiller DJ. Hardie I. et al. Comparison of three immunosuppressive regimens in cadaver renal transplantation: long-term cyclosporin. short term cyclosporin followed by azathioprine and prednisolone and azathioprine and prednisolone without cyclosporin. N Engl J Med 1988 Jun: 318: 1499-507
7. Myers BD. Ross J. Newton L. et al. Cyclosporin-associated chronic nephropathy. N Engl J Med 1984; 311: 699-705
8. Rao KV. Crosson JT. Kjellstrand CM. Chronic irreversible nephrotoxicity from cyclosporin A. Nephron 1985: 41: 75-7
9. Calne RY. Rolles K. Thiru S. et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs. Lancet 1979 Nov: 11: 1033-6
10. Bieber PB. ReitzBA. Jamieson SW, et al. Malignant lymphoma in cyclosporin Atreated alloeraft recipients. Lancet 1980 Jan: 1: 43
11. Morris PJ, French ME. Dunnill M.S. et al. A controlled trial of cyclosporin in renal transplantation with conversion to azathioprine and prednisolone after three months. Transplantation 1983; 36: 273-7
12. Morris PJ, Alien RD. Thompson JF. et al. Cyclosporin conversion versus conventional immunosuppression: long-term follow-up and histological evaluation. Lancet 1987 Mar: I: 586-91
13. Land W. Castro LA. Hillebrand G. et al. Conversion rejection consequences by changing the immunosuppressive therapy from cyclosporin to azathioprine after kidney transplantation. Transplant Proc 1983: 15: 2857-61
14. Adu D, Michael J. McMaster P. Conversion from cyclosporin to azathioprine/prednisolone. Lancet 1985 Feb; 1: 392
15. Hoitsma AJ. van Lier HJJ. Wetzels JFM. et al. Cyclosporin treatment with conversion after three months versus conventional immunosuppression in renal allograft recipients. Lancet 1987 Mar: 1: 584-6
16. Kootte AMM. Lensen LM. van Es LA. et al. Controlled cyclosporin conversion at three months after renal transplantation. Transplantation 1988 Nov: 46: 677-80
17. Kootte AMM. Lensen LM. van Bockel JH. et al. High- and low-dose regimens of cyclosporin in renal transplantation: immunosuppressive efficacy and side effects. Nephrol Dial Transplant 1988: 3: 666-7(1
18. Hollander AAMJ. van Saase JLCM, Kootte AMM. et al. Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation. Lancet 1995 Mar; 345: 610-4
19. Sagalowsky Al. Reisman ME. Dawidson 1. et al. Late cyclosporin conversion carries risk ot irreversible rejection. Transplant Proc 1988:20: 157-60
20. Spielherger M. Aigner F. Schmid T, et al. Long term results of cadaveric renal transplantation after conversion from cyclosporin to azathioprine: a controlled randomized trial. Transplant Proc 1988: 20: 169-70
21. Delmonico FL. Conti D. Auchincloss H. et al. Long-term, lowdose cyclosporin treatment of renal allograft recipients. Transplantation 1990 May; 49: 899-904
22. Watson MA. Briggs JD. Junor BJR. et al. Randomized trial ol conversion from cyclosporin to azathioprine at one year after renal transplantation. Transplant Proc I9H9 Feh: 21: 1583-4
23. Sweny P. Lui SF. Scohle JE. et al. Conversion of stähle renal allografts at one year from cyclosporin A to azathioprine: a randomized controlled study. Transplant Int 1990: 3: 19-22
24. Pedersen EB. Hansen HE. Oison S. et al. Comparison between the effects of cyclosporin and azathioprine on functional and morphologic renal parameters in a randomized study from 12 to 24 months after renal transplantation. Clin Transpl 1991 : 5:456-66
25. Pedersen EB. Hansen HE. Kornerup HJ, et al. Long-tenu graft survival after conversion from cyclosporin to u/uthioprine I year after renal transplantation: a prospective, randomized study from I to 6 years after transplantation. Nephrol Dial Transplant 1993; X: 250-4
26. Flechner S M. van Buren CT. Kerman R. et al. The effect of conversion from cyclosporin to a/athioprine immunosuppression for intractable nephrotoxicity. Transplant Proc 1983 Dec: 15: 2869-73
27. Flechner SM, van Buren CT. Jarowenko M. et al. The fate of patients converted from cyclosporin to azathioprine to improve renal function. Transplant Proc 1985 Feh: 17: 1227-30
28. Flechner SM. Lorher M. van Buren CT. et al. The case against conversion to azathioprine in cyclosporin-treated patients. Transplant Proc 1985 Aug: 17: 276-81
29. Canafax DM. Sutherland DER. Ascher ML. et al. Cyclosporin nephrotoxicity in renal allografi recipients: conversion to a/athioprine to improve renal function. Transplant Proc 1983 Dec: 15: 2874-7
30. Canafax DM. M artel EJ, Sutherland DER. et al. Management of cyclosporin nephrotoxicity by conversion to azathioprine or by reduction of cyclosporin dose and addition of azathioprine. Transplant Proc 1985 Dec: 17: 2677-8
31. Rolles K. Merion R. Calne RY. Conversion problem - azathioprine to cyclosporin. Transplant Proc 1983 Dec: 15: 2878-80
32. Rocher LL. Milford EL. Kirkman RL. et al. Conversion from cyclosporin to a/athioprine in renal allograft recipients. Transplantation 1984 Dec: 3: 669-74
33. Carpenter CB. Milford EL. Kirkman RL. et al. Stability ol renal allograft recipients after conversion from cyclosporin to a/a-thioprine. Transplant Proc 1985 Aug: 17: 261-5
34. Thistlethwaite JR. Haag BW. Jones KW. et al. Elective corner sion from cyclosporin to azathioprine in recipients with stable renal function 6 months after kidney transplantation. Hum Immunol 1985: 14: 314-23
35. Vanrenterghem Y. Michielsen PA. A control led trial of one versus three months' cyclosporin and conversion to azathioprine in renal transplantation. Transplant Proc 1985:17 Feh: 1162-3
36. MacDonald AS. Belitsky R Gupta R. et al. Conversion from cyclosporin to azathioprine in renal graft recipients. Trans plant Proc 1985 Aug: 17: 1940-2
37. Versluis DJ. Wenting GJ. Derkx FH. et al. Who should he con verted from cyclosporin to conventional immunosuppression in kidney transplantation, and why. Transplantation 1987 Sept: 44: 387-9
38. Tegzess AM. van Son WJ. Beeten JM. et al. Improvement of renal function after conversion from cyclosporin only to prednisolone-azathioprine followed by late-onset graft fail ure in renal transplant patients. Transplant Proc 1987 Feh: 19: 2(XK)-4
39. Tegzess AM. van Son WJ, Beelen JM. et al. Elective conversion from cyclosporin to a/athioprine and prednisolone in patients after cadaveric renal transplantation: ohscrxations on graft survival and renal function. Transplant Proc 1989 Feb; 21: 1635-7
40. Maddux MS, Veremis SA, Pollak R, et al. Conversion from cyclosporin to azathioprine improves renal function without increased risk of graft failure. Transplant Proc 1987 Feb; 19: 2007-9
41. Maddux MS, Veremis SA, Bauma WD, et al. Conversion from cyclosporin to azathioprine after renal transplantation: longterm effects on renal function, rejection, and allograft survival. Transplant Proc 1988 June; 20: 152-4
42. Adams PL, Burkart JM, Hamilton RW, et al. Safe conversion from cyclosporin. Transplant Proc 1987 Feb; 19: 2010-1
43. Freedman Bl, Tuttle AB, Lorentz WB, et al. Conversion from cyclosporin: status after five years. Transplant Proc 1991 Feb; 23: 1020-2
44. Oka T, Omori Y, Aikawa I, et al. The fate of living-related donor kidney recipients after conversion from cyclosporin to azathioprine. Transplant Proc 1987 Feb; 19: 2012-6
45. Oka T, Omori Y, Aikawa I, et al. Combination therapy of cyclosporin and azathioprine in living-related kidney transplant recipients compared with patients converted totally from cyclosporin to azathioprine. Transplant Proc 1988 Jun; 20: 143-6
46. Oka T, Omori Y, Aikawa I, el al. Early conversion from cyclosporin to combination therapy with azathioprine in living-related kidney transplantation. Transplant Proc 1989 Feb; 21: 1628-30
47. Veitch PS, Taylor JD, Feehally J, et al. Elective conversion from cyclosporin to azathioprine: long-term follow up. Transplant Proc 1987 Feb; 19: 2017
48. Gonwa TA, Nghiem DD, Corry RJ. Results of conversion from cyclosporin to azathioprine in cadaveric renal transplantation. Transplantation 1987; 43: 225-8
49. Shen SY, Zemel SM, Weir MR, et al. Conversion of cyclosporin to azathioprine in renal transplant patients. Transplant Proc 1987 Feb; 19:2032-6
50. Zemel SM, Shen S Y, Weir MR, et al. Effects of HLA-matching and panel reactive antibodies in the development of rejection after conversion of cyclosporin to azathioprine. Transplant Proc 1987 Feb; 19:2029-31
51. Shen SY, Weir MR, Coughlin TR. Renal allograft biopsy and conversion of cyclosporin to azathioprine. Transplantation 1989 Feb; 47: 223-9
52. Lennard TWJ, Venning M, Donnelly PK, et al. Conversion of immunosuppression in renal allograft recipients from cyclosporin to azathioprine and prednisolone 6 months after transplantation. Transplant Proc 1987 Feb; 19: 3594-6
53. Venning MC, Lennard TWJ, Stevens ME, et al. Cyclosporin A treatment with successful selective conversion after six months in 70 renal allograft recipients. Transplant Proc 1989 Feb; 21: 1633-4
54. Sobh MA, Shebab Eidein AB, Moustafa FE, et al. Elective conversion from cyclosporin to azathioprine in living-related donor kidney transplants. Nephrol Dial Transplant 1987; 2: 258-60
55. Ubhi CS, Baker JM, Guillou PJ, et al. Fine-needle aspiration cytology of elective conversion from cyclosporin to azathioprine and prednisolone. Nephrol Dial Transplant 1988: 3: 453-7
56. Jacobson JE, Pontin A, van Zyl-Smit R, et al. Results of conversion immunosuppression in 193 cadaver and 42 living-related donor renal allografts. Transplant Proc 1988 Jun; 20: 155-6
57. Ovnat A, Pontin AR, Cassidy MJD, et al. Long-term results with conversion from cyclosporin to azathioprine at 3 months after renal transplantation. Transplant Proc 1992 Oct; 24: 1698-9
58. Kahn D, Ovnat A, Pontin AR, et al. Long-term results with elective cyclosporin withdrawal at three months after renal transplantation: appropriate for living-related transplants'? Transplantation 1994 Dec; 58: 1410-2
59. Abbud-Filho M, Ramalho HJ, Barberato JB, et al. A prospective study of conversion from cyclosporin to azathioprine: comparison of clinical and morphological findings. Transplant Proc 1988Jun;20: 164-8
60. Abbud-Filho M, Barberato JB, Ramalho HJ, et al. Consequences of conversion from cyclosporin to conventional therapy in renal transplantation. Transplant Proc 1989 Feb; 21: 1638-40
61. Paraiso AR, Ona ET, Alano FA, et al. Immunosuppressive conversion from cyclosporin to azathioprine in renal transplant patients. Transplant Proc 1989 Feb; 21: 1627
62. Helling TS, Wood BC, Nelson PW, et al. Elective conversion from cyclosporin to azathioprine in sensitized patients following cadaveric renal transplantation. Am J Kidney Dis 1990 Feb; 15: 137-40
63. Sutherland F, Burgess, Klassen J, et al. Post-transplant conversion from cyclosporin to azathioprine: effect on cardiovascular risk profile. Transpl Int 1993; 6: 129-32
64. Hilbrands LB, Hoitsma AJ, Koene RAP. Randomized, prospective trial of cyclosporin monotherapy versus azathioprineprednisone from three months after renal transplantation. Transplantation 1996 Apr; 61: 1038-46
65. Elion GB, Callahan S, Bieber S, et al. A summary of investigations with 6-[(l-methyl-4-nitro-r-imidazolyl)thio] purine. Cancer Chemother Rep 1961; 14: 93-8
66. Elion GB. Symposium on immunosuppressive drugs. Biochemistry and pharmacology of purine analogues. Fed Proc 1967; 26: 898-904
67. Chan GLC, Canafax DM, Johnson CA. The therapeutic use of azathioprine in renal transplantation. Pharmacotherapy 1987; 7: 165-77
68. Walker RG, d'Apice AJF. Azathioprine and steroids. In: Morris PJ, editor. Kidney transplantation. 3rd ed. Philadelphia: W.B Saunders, 1988:319-41
69. Odlind B, Hartvig P, Lindstrom B, et al. Sérum azathioprine and 6-mercaptopurine levels and immunosuppressive activity after azathioprine administration in urémie patients. Int J Immunopharmacol 1986; 8: 1-11
70. Lennard L, Maddocks JL. Assay of 6-thioguanine nucleotide, a major metabolite of azathioprine, 6-mercaptopurine and 6thioguanine in human red blood cells. J Pharm Pharmacol 1983;35: 15-8
71. Lennard L, van Loon JA, Lilleyman JS. Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyllransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther 1987; 41: 18-25
72. Lake KD, Canafax DM. Important interactions of drugs with immunosuppressive agents used in transplant recipients. J Antimicrobial Chemother 1995; 36: Suppl. B: 11-22
73. Kerstens PJSM, Stolk JN, Hilbrands LB, el al. 5'-Nucleotidase and azalhioprine-related toxicity. Lancet 1993; 342: 1245-6
74. Kahan BD. Cyclosporin. N Engl J Med 1989 Dec; 321: 1725-38
75. Faulds D, Goa KL, Benfield P. Cyclosporin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 1993 Jun: 45:953-1040
76. Drewc J. Beglinger C. Kissel T. The absorption site of cyclosporin in the human gastrointestinal tract. Br J Clin Pharmacol 1992; 33: 39-43
77. Kahan BD. Ried M. Newburger J. Pharmacokinetics of cyclosporin in human renal transplantation. Transplant Proc 1983: 15: 446-53
78. Gupta SK. Manfro RC. Tomlanovieh SJ. et al. Elïect of food on the pharmacokinetics of cyclosporin in healthy subjects following oral and intravenous administration. J Clin Pharmacol 1990:30: 643-53
79. Hollander AAMJ. van Rooy J, Lentjes EGWM. et al. The effect of grapefruit juice on cyclosporin and prednisone metabolism in transplant patients. Clin Pharmacol Ther 1995 Mar: 57: 318-24
80. Kronbach T. Fischer V. Meyer UA. Cyclosporin metabolism in human liver: identification of a cytochrome P450 III gene family as the major cyclosporin metabolizing cn/yme explains interactions of cyclosporin with other drugs. Clin Pharmacol Thcr 1988:43:6305
81. Kolars JC. Awni WM. Merion RM. et al. First pass metabolism of cyclosporin by the gut. Lancet 1991; 338: 1488-90
82. Yee GC. McGuire TR. Phannacokinetic drug interactions with cyclosporin (Part II. Clin Pharmacokinet 1990: 19: 319-32
83. Yee GC. McGuire TR. Pharmacokinetic drug interactions with cyclosporin (Part 11). Clin Pharmacokinet 1990; 19: 400-15
84. Kahan BD. Grevel J. Overview: optimization of cyclosporin therapy in renal transplantation by a phurmacokinclic strategy. Transplantation 1988: 46: 63
85. Atkinson K. Biggs J. Darveniza P. et al. Cyclosporin-associated central nervous system toxicity after allogeneic bone marrow transplantation. Transplantation 1984 Jul; 38: 34-7
86. Bcrden JHM. Hoilsma AJ. Merx JL. et al. Severe central nervous system toxicity associated with cyclosporin. Lancet 1985 Jan: I: 219-20
87. Wilczek H. Ringden O. Tyden G. Cyclosporin-associated central nervous system toxicity after renal transplantation. Transplantation 1985: 39: 110
88. Rubin AM. Transient cortical blindness and occipital Scizures with cyclosporin toxicity. Transplantation 1989 Mar: 47: 572-3
89. Palmer BF. Tolo RD. Severe neurologic toxicity induced by cyclosporin A in three renal transplant patients. Am J Kidney Dis 1991 Jul: 18: 116-21
90. Van Buren D. Van Buren CT. Flechner SM. et al. Dt' HOYII hemolytic urémie syndrome in renal transplant recipients immtinosuppressed with cyclosporin. Surgery 1985: 98: 54-62
91. Wolfe JA. McCann RL. Sanfilippo F. Cyclosporin-associated microangiopathy in renal transplantation: a severe but potentially reversible form of early graft injury. Transplantation 1986:41:541-4
92. Kasiskc BL. Heim-Duthoy K. Ma JZ. Elective cyclosporin withdrawal after renal transplantation: a mela-analysis. JAMA 1993: 269: 395-400
93. Curtis JJ. Luke RG. Duhovsky E. et al. Cyclosporin in therapeutic doses increases renal allograft vascular resistance. Lancet 1986 Aug: 11:477-9
94. Zictse R. van lerland ML. Derkx FHM.et al. Glomerular barrier function following conversion from cyclosporin to azathioprine in renal transplant patients. Am J Kidney Dis 1994 Dec: 24:927-31
95. Paul LC. Fellström B. Chronic vascular rejection of the heart and the kidney: have rational treatment options emerged? Transplantation 1992Jun;53: 1169-79
96. Widstam-Attorps U. Bergslrom J. Lefvert AK. Five year fol low -up of graft function and urinary protein excretion in kid-ney transplant patients immunosuppressed with cyclosporin or azathioprine. Transplant Proc 1990 Feh: 22: 216
97. European Multicentre Trial Group. European multicentre trial of cyclosporin in renal transplantation: 10 year follow-up. Transplant Proc 1993 Feb: 25: 527-9 OX.
98. Ruggenenti P. Perico N. Amuchastegui S. et al. Following an initial decline, glomerular filtration rate stabilizes in heart transplant patients on chronic cyclosporin. Am J Kidney Dis 1994 Oct: 24: 549-53
99. Burke JF. Pirsch JD. Ramos EL. et al. Long-term efficacy and safety of cyclosporin in renal transplant recipients. N Engl J Med'l 994 Aug: 33 1: 358-63
100. Curtis JJ. Hypertension after renal transplantation: cyclosporin increases the diagnostic and therapeutic considerations. Am J Kidney Dis 1989Jun: 13: 28-32
101. Moss NO. Powell SL. Falk RJ. Intravenous cyclosporin activates afferent and efferent renal nerves and causes sodium retention in innervated kidneys in rats. Proc Natl Acad Sci USA 1085:82:8222-6
102. Schcrrer U. Vissing SF. Morgan BJ. et al. Cyclosporin-induccd sympathetic activation and hypertension after heart transplantalion. N Engl J Med 1990: 323: 693-9
103. Mark AL. Cyclosporin. sympathetic activity, and hypertension. N Engl J Med 1990: 323: 748-50
104. Perico N, Benign! A. Zojz C. et al. Functional significance of exaggerated renal throinhoxane A2 synthesis induced by cyciosporin A. Am J Physiol 1986: 251: 581-7
105. Kon V. Sugiura M. Inagami T. et al. Role of endothclin in cyclosporin induced glomerular dysfunction. Kidney Int 1990: 37: 1487-91
106. Curtis JJ. Luke RG. Jones P. et al. Hypertension in cyclosporintreated renal transplant recipients is sodium dependent. Am J Med 1988:85: 134-8
107. Curtis JJ. Hypertension following kidney transplantation. Am J Kidney Dis 1994 Mar: 23: 471-5
108. van der Schaaf MR. Hene RJ. Floor M. et al. Hypertension after renal transplantation; calcium channel or converting enzyme blockade'.'Hypertension 1995 Jan: 25: 77-81
109. Markell MS. Brown CD. Butt KMH. et al. Prospective evaluation of changes in lipid profiles in cyclosporin-lreated renal transplant patients. Transplant Proc 1989: 21: 1497-9
110. Kasiske BL.Tortorice KL. Heim-Duthoy KL. et al. The adverse impact of cyclosporin on serum lipids in renal transplant recipients. Am J Kidney Dis 1991: 17: 700-7
111. Webb AT. Reavclcy DA. O'Donnell M. et al. Does cyclosporin increase lipoprotein(a) concentrations in renal transplant recipients.' Lancet 1993 Jan: 341: 268-70
112. Hilbiands LB. Demacker PN. Hoitsma AJ. et al. The effects of cyclosporin and prcdnisone on serum lipid and (apo)lipoprotein le\els in renal transplant recipients. J Am Soc Nephrol 1995 Jun: S (12): 2073-81
113. Yagisav-a T. Takahashi K. Teraoke S. et al. Deterioration in glucose metabolism in cyclosporin-treated kidney transplant recipients and rats. Transplant Proc 1986: 18: 1548-51
114. Robertson RP. Cyclosporin-induccd inhibition of insulin secrelion in isolated rat islets and HIT cells. Diabetes 1986: 35: 1016-9
115. Osi L. Tyden G. Fehrman I. Impaired glucose tolerance in cvclosporm-prednisolone-treated renal graft recipients. Transplantation 1988: 46: 370-2
116. Tiller DJ. Hall BM. Horvarth JS. et al. Gout and hyperuricae mia in patients on cyclosporin and diuretics. Lancet 1985 Feh: I: 453
117. West C, Carpenter BJ, Hakala T. The incidence of gout in renal transplant recipients. Am J Kidney Dis 1987 Nov; 10: 369-71
118. Lin H, Rocher LL, McQuillan MA, et al. Cyclosporin-induced hyperuricemia and gout. N Engl J Med 1989; 321: 287-92
119. Noordzij TC. Leunissen KML, van Hooff JP. Renal handling of urate and the incidence of gouty arthritis during cyclosporin and diuretic use. Transplantation 1991 Jul; 52: 64-7
120. Showstack J, Katz P. Amend W, et al. The association of cyclosporin with the 1-year costs of cadaver-donor kidney transplants. JAMA 1990; 264: 1818-23
121. Yilmaz S, Hayry P. The impact of acute episodes of rejection on the generation of chronic rejection in rat renal allografts. Transplantation 1993; 56: 1153-6
122. Almond PS, Matas A, Gillingham A, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993 Apr; 55: 752-7
123. van Saase JLCM, van der Woude FJ, Thorogood J, et al. The relation between acute vascular and interstitial renal allograft rejection and subsequent chronic rejection. Transplantation 1995:59: 1280-5
124. Heim-Duthoy KL, Chitwood KK, Tortorice KL, et al. Elective cyclosporin withdrawal I year after renal transplantation. Am J Kidney Dis 1994 Nov; 24: 846-53
125. Wickramasinghe SN, Dodsworth H, Rault RMJ, et al. Observation on the incidence and cause of maerocytosis in patients on azathioprine therapy following renal transplantation. Transplantation 1974; 18:443-6
126. Connell WR, Kamm MA, Ritchie JK, et al. Bone marrow toxicily caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993; 34: 1081-5
127. Pruijt JFM, Haanen JBAG, Hollander AAMJ, et al. Azathioprine-induced pure red-cell aplasia. Nephrol Dial Transplant 1996 July; II: 1371-3
128. Degott C, Rueff B, Kreis H, et al. Peliosis hepatis in récipients of renal transplants. Gut 1978; 19:748-53
129. Gerlag PGG, Lobatto S, Driessen WMM. et al. Hepatic sinusoidal dilatation with portal hypertension during azathioprine treatment after kidney transplantation. J Hepatol 1985; 1: 339-48
130. Katzka DA, Saul SH, Jorkasky D, et al. Azathioprine and hepatic venocclusive disease in renal transplant patients. Gastroenterology 1986 Feb; 90: 446-54